Thailand Compulsory-Licensing Plan To Proceed Despite New Government
This article was originally published in PharmAsia News
Although Thailand's military-appointed government is to be replaced soon by an elected government, plans to impose compulsory licensing on four cancer drugs are to proceed as planned. Public Health Minister Mongkol Na Songkhla said the decision was made on Jan. 4 and the pros and cons of the action had been thoroughly considered. Believed targeted for facing generic versions are letrozole and imatinib by Novartis, docetaxel by Sanofi-Aventis and erlotinib by Roche Holding. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.